

2019-09-01

## Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States

Adeyinka Adejumo  
*University of Massachusetts Medical School*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>

 Part of the [Clinical Epidemiology Commons](#), [Digestive System Diseases Commons](#), [Epidemiology Commons](#), [Gender and Sexuality Commons](#), [Health Services Administration Commons](#), [Health Services Research Commons](#), and the [Race and Ethnicity Commons](#)

---

### Repository Citation

Adejumo A, Samuel GO, Adegbala OM, Adejumo KL, Ojelabi O, Akanbi O, Ogundipe OA, Pani L. (2019). Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States. Open Access Articles. <https://doi.org/10.20524/aog.2019.0402>. Retrieved from <https://escholarship.umassmed.edu/oapubs/3970>

Creative Commons License



This work is licensed under a [Creative Commons Attribution-NonCommercial-Share Alike 3.0 License](#). This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

# Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States

Adeyinka Charles Adejumo<sup>a,b,c,d</sup>, Gbeminiyi Olanrewaju Samuel<sup>e</sup>, Oluwole Muyiwa Adegbala<sup>f</sup>, Kelechi Lauretta Adejumo<sup>d</sup>, Ogooluwa Ojelabi<sup>c</sup>, Olalekan Akanbi<sup>g</sup>, Olumuyiwa Akinbolaji Ogundipe<sup>h</sup>, Lydie Pani<sup>a,b</sup>

North Shore Medical Center, Salem, MA; Tufts University Medical School, Boston, MA; University of Massachusetts Medical School, Worcester, MA; University of Massachusetts Lowell, MA; Englewood Hospital and Medical Center, NJ; University of Kentucky College of Medicine; St. Cloud State University, Plymouth, MN, USA

## Abstract

**Background** As the frequency of nonalcoholic fatty liver disease (NAFLD) continues to rise in the United States (US) community, more patients are hospitalized with NAFLD. However, data on the prevalence and outcomes of hospitalizations with NAFLD are lacking. We investigated the prevalence, trends and outcomes of NAFLD hospitalizations in the US.

**Methods** Hospitalizations with NAFLD were identified in the National Inpatient Sample (2007-2014) by their ICD-9-CM codes, and the prevalence and trends over an 8-year period were calculated among different demographic groups. After excluding other causes of liver disease among the NAFLD cohorts (n=210,660), the impact of sex, race and region on outcomes (mortality, discharge disposition, length of stay [LOS], and cost) were computed using generalized estimating equations (SAS 9.4).

**Results** Admissions with NAFLD tripled from 2007-2014 at an average rate of 79/100,000 hospitalizations/year ( $P<0.0001$ ), with a larger rate of increase among males vs. females (83/100,000 vs. 75/100,000), Hispanics vs. Whites vs. Blacks (107/100,000 vs. 80/100,000 vs. 48/100,000), and government-insured or uninsured patients vs. privately-insured (94/100,000 vs. 74/100,000). Males had higher mortality, LOS, and cost than females. Blacks had longer LOS and poorer discharge destination than Whites; while Hispanics and Asians incurred higher cost than Whites. Uninsured patients had higher mortality, longer LOS, and poorer discharge disposition than the privately-insured.

**Conclusions** Hospitalizations with NAFLD are rapidly increasing in the US, with a disproportionately higher burden among certain demographic groups. Measures are required to arrest this ominous trend and to eliminate the disparities in outcome among patients hospitalized with NAFLD.

**Keywords** Ethnicity, charge, length of stay, cost, discharge disposition

*Ann Gastroenterol* 2019; 32 (5): 504-513

Department of <sup>a</sup>Medicine, North Shore Medical Center, Salem, MA (Adeyinka Charles Adejumo, Lydie Pani); <sup>b</sup>Medicine, Tufts University Medical School, Boston, MA (Adeyinka Charles Adejumo, Lydie Pani); <sup>c</sup>Medicine, University of Massachusetts Medical School, Worcester MA (Adeyinka Charles Adejumo, Ogooluwa Ojelabi); <sup>d</sup>Public Health Program, University of Massachusetts Lowell, Lowell, MA (Adeyinka Charles Adejumo, Kelechi Lauretta Adejumo);

<sup>e</sup>Medicine, East Carolina University, Vidant Health Center, Greenville, NC (Gbeminiyi Olanrewaju Samuel); <sup>f</sup>Medicine, Englewood Hospital and Medical Center, Englewood, NJ (Oluwole Muyiwa Adegbala); <sup>g</sup>University of Kentucky College of Medicine, Division of Hospital Medicine, Lexington, KY (Olalekan Akanbi); <sup>h</sup>Applied Clinical Research Program, St. Cloud State University, Plymouth, MN (Olumuyiwa Akinbolaji Ogundipe), USA

Conflict of Interest: None

Received 17 April 2019; accepted 24 June 2019; published online 17 July 2019

DOI: <https://doi.org/10.20524/aog.2019.0402>

Correspondence to: Adeyinka Charles Adejumo, MD, MS, Department of Medicine, North Shore Medical Center, 81 Highland Ave., Salem MA 01970, USA, e-mail: [acadejumo@partners.org](mailto:acadejumo@partners.org)

## Introduction

With the increasing adoption of the Western diet and sedentary lifestyle, the prevalence of obesity, insulin resistance, type II diabetes, lipid disorders, and metabolic syndrome has been increasing [1-3]. Individuals with these disorders have a propensity to accumulate abnormal fat deposits in their liver; this is called nonalcoholic fatty liver disease (NAFLD). NAFLD is currently the most common liver disease and is estimated to affect 33% of adults worldwide (approx. 1 billion) [1]. NAFLD may progress to hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma [2-4]. NAFLD represents a spectrum of liver diseases ranging from simple steatosis, steatohepatitis, to fibrosis and cirrhosis, with an increased risk for hepatocellular carcinoma. Clinical outcomes are poorer as patients' progress from the benign end of the spectrum (steatosis) to the severe phenotypes [5-7].

Although studies have reported the rising prevalence of NAFLD in the community [8-10], the occurrence and burden among hospitalized patients have not been studied. Furthermore, gender, racial, socioeconomic, and regional disparities have been revealed in both prevalence and management outcomes for NAFLD-associated conditions [11,12]. However, no study has evaluated such disparities among patients hospitalized with NAFLD.

Considering the alarming increase in NAFLD and that end-stage liver disease from NAFLD is projected to be the number one reason for liver transplantation by 2020 [13], it is essential to evaluate the burden of and disparities among NAFLD-associated hospitalizations in the United States (US). This will allow early formulation of public health measures to quickly arrest any ominous trend. Therefore, we carried out this population-based study to investigate the prevalence and trends in the NAFLD in different demographic categories and the disparities among hospitalization outcomes of subjects admitted with NAFLD. We hypothesized that the prevalence and burden of NAFLD among hospitalized patients would be increasing, mirroring the pattern in the community.

## Patients and methods

### Data source

A retrospective cross-sectional analysis of the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) database was performed. The NIS is administered by the Agency for Healthcare Research and Quality, through a multi-stage clustered sampling by states, strata, and hospitals within the US for every year. Data from each year represent 20% of all the discharges across over 4500 non-federal community hospitals (public and academic centers) from about 40 states. Currently, 40 of 50 states in the US participate in the NIS. Each year of the NIS has about 7 million hospitalization records (weighted to 35 million hospitalizations) [14]. The NIS provides a fairly accurate representation of hospitalizations, because all the large and diverse states in the US participate in the program,

including California, Florida, Texas, and New York. In this study, we used data from the years 2007-2014 (n=61,324,882) that contained per discharge 15 procedures and about 25-30 diagnoses all coded with the International Classification of Diseases, 9<sup>th</sup> revision, Clinical Modification (ICD-9-CM) codes. Since the NIS is a completely de-identified publicly available data, no Institutional Review Board approval was required.

### Study population and variables

After using the ICD-9-CM code of 571.8 to abstract records for patients aged 18 years and above with a discharge diagnosis of NAFLD (n=307,651, 0.009%), we eliminated records with other chronic liver disease—alcoholic liver disease, hemochromatosis, hepatitis C and B virus, primary biliary cirrhosis, autoimmune hepatitis, toxic liver disease, and other poorly defined liver diseases—and those with an organ transplant (Fig. 1 and Supplementary Table 1). The ICD-9-CM code for NAFLD has been used by many recent studies [15-20]. We also eliminated records with missing inputs, and abstracted demographic, patient, and hospital-related information. All the information used in this study either consisted of variables already available within the dataset or was created by us. We had 4 primary outcome variables: total hospital charge (THC; in US dollars), duration of hospitalization (length of stay in days: LOS), in-hospital mortality, and unfavorable disposition on discharge. For the THC we inflated the values before 2014 to the 2014 levels, using the Consumer Price Index from the US Bureau of Labor. Unfavorable disposition on discharge was derived from a multinomial variable in NIS to generate a binary variable: routine to home/home healthcare (as favorable) vs. transfer to another health facility (short-term acute hospital, skilled nursing, intermediate care, psychiatric, or rehabilitation centers) as unfavorable.

We collected demographic information on sex (male and female), race (Whites, Blacks, Hispanics, and others [Asian, Pacific Islanders, Native Americans, and others]), health insurance (government [Medicare, Medicaid], private, and others [self-pay, uninsured and other charges]), and median household income of residence zip-code (first to fourth quartile). We also extracted comorbid clinical conditions using the ICD-9-CM codes. Over 50 comorbid conditions were selected and combined to produce the Deyo-Charlson index, an extensively studied and widely used guide [21]. These comorbidities captured chronic diseases across all the systems in the body and have been used in many studies [22-26]. Furthermore, since the outcomes of liver diseases vary with the severity of liver injury, we stratified the NAFLD subjects into three, based on the Baveno IV consensus criteria: no cirrhosis, compensated cirrhosis, and decompensated cirrhosis [27]. Cirrhosis and its decompensation (hepatorenal syndrome, jaundice, hepatic encephalopathy, ascites, variceal bleeding, and portal hypertension) were identified through ICD-9-CM codes (Supplementary Table 1). The Baveno IV classification has been extensively used and validated in the HCUP-NIS for the reliable identification of liver cirrhosis and assessment of its severity [28]. Finally, hospital characteristics that could impact

**Table 1** Characteristics of patients hospitalized with nonalcoholic fatty liver disease (NAFLD) in the US from 2007-2014 by sex


Characteristics	Male n=83886 (~410054)	Female n=126774 (~619253)	P-value
Age, mean (SD), years	54.12 (15.1)	54.36 (15.8)	0.0136
Race, %			<0.0001
Whites	73.51	70.03	
Blacks	7.67	9.56	
Hispanics	12.94	15.06	
Others	5.88	5.35	
Health Insurance, %			<0.0001
Government	43.81	51.42	
Private	43.84	39.12	
Self-pay & others <sup>1</sup>	12.35	9.46	
Income, %			<0.0001
Lowest quartile	24.88	27.85	
Second quartile	24.92	25.98	
Third quartile	25.53	24.92	
Highest quartile	24.67	21.26	
Region, %			<0.0001
Northeast	18.32	16.85	
Midwest	17.04	17.55	
South	41.75	43.02	
West	22.90	22.57	
Hospital teaching status, %			0.0406
Rural	8.64	8.99	
Urban non-teaching	42.89	42.23	
Urban teaching	48.48	48.77	
Charlson-Deyo comorbidity index, %			<0.0001
Deyo: 0	32.45	32.56	
Deyo: 1-3	47.56	50.40	
Deyo: >3	19.99	17.04	
Liver cirrhosis, %			<0.0001
No cirrhosis	95.76	94.81	
Compensated cirrhosis	1.93	2.39	
Decompensated cirrhosis	2.31	2.80	
In-hospital mortality, %	1.16	1.02	0.0033
Discharge disposition, %			0.0574
Home	88.16	87.86	
Rehabilitation and acute care facility	11.84	12.14	
LOS, days	4.75	4.55	<0.0001
THC, \$	47026.00	42848.00	<0.0001

<sup>1</sup>Self-pay & others: no charge, other government, Indian Health Service, Worker's compensation, other miscellaneous  
LOS, length of stay in hospital; THC, total hospitalization cost

outcomes were determined from the dataset and included hospital region (Northeast, South, Midwest and West), and hospital teaching status (rural, urban-nonteaching and urban-teaching).

### Statistical analysis

Analyses were performed using the Statistical Analysis System (SAS V.9.4, SAS Institute Inc., Cary, NC, US). In all



**Figure 1** Selection flowchart for patients hospitalized for nonalcoholic fatty liver disease (NAFLD) in the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) data 2007-2014

the statistical models, a P-value of <0.05 was chosen *a priori*. We reported the effect estimates, P-values and 95% confidence intervals (CI), or the Bonferroni corrected P-values for multiple comparisons. Patients' clinical characteristics were reported as mean and standard deviation (SD) for continuous variables with normal distributions, and as a median and inter-quartile range (IQR) for either continuous or counting variables without a normal distribution. Similarly, statistical tests were carried out using the chi-square test and percentages for the categorical variables, and Student's *t*-test and the Wilcoxon test for numeric variables with normal and non-normal distributions, respectively. The trends were estimated using general linear models with NAFLD as outcome and year as a predictor. Other demographic factors were added to the model and their interaction with year was tested with a P-trend <0.01 set as significance. The adjusted odds ratio (AOR) was calculated with multivariate regressions using generalized estimating equations with the predictors (demographics, patient and hospital characteristics) and each of the 4 outcomes. Binary (mortality and discharge disposition), discrete numeric variables with over-dispersed count distributions (LOS), and continuous variables with a right-skewed spread (THC) were modeled with binary logistic, negative binomial and gamma functions, respectively. As recommended by HCUP, all analysis was performed with the STRATA, CLUSTER and WEIGHT for the

SURVEYLOGISTIC, SURVEYFREQ and SURVEYMEANS procedures to account for the complex clustered sampling methodology [29]. For the GENMOD procedures, the CLASS, WEIGHT and REPEATED statements were used to account for these complex and in-hospital correlations [30].

## Results

### Baseline characteristics of patients hospitalized with NAFLD

The total of 210,660 hospitalized patients with NAFLD were more likely to be female (60.16% vs. 39.84%), with a similar mean age of 54 (Table 1). Compared to males, females were slightly less likely to be White (70.03% vs. 73.51%) but more likely to be Black (9.56% vs. 7.67%) or Hispanic (15.06% vs. 12.94%). Females were more likely to be on governmental health insurance (51.42% vs. 43.81%) but less likely to be on private plans (39.12% vs. 43.84%) or uninsured (9.46% vs. 12.35%). They had a higher frequency of compensated (2.39% vs. 1.93%) and decompensated (2.80% vs. 2.31%) cirrhosis. The most common primary diagnoses during hospitalizations with NAFLD were morbid obesity, acute pancreatitis, and septicemia, in that order (Supplementary Table 2).

While the in-hospital mortality rate was lower among females (1.02% vs. 1.16%), the discharge disposition was similar across both sexes. The LOS was shorter (4.55 vs. 4.75 days) and THC lower (\$42,848.00 vs. \$47,026.00) among females compared with males.

### Predictors of inpatient mortality

Only increasing age, sex, health insurance, hospital region and teaching status, Charlson-Deyo comorbidity, and liver cirrhosis were significantly associated with mortality (Table 2). The odds of dying increased by 36% for every 10-year increase in age (AOR 1.36, 95%CI 1.31-1.42;  $P<0.0001$ ), by 14% among individuals without health insurance/self-pay vs. those with private insurance (AOR 1.14, 95%CI 1.09-1.67;  $P=0.002$ ). Mortality was also higher among NAFLD hospitalizations in urban centers vs. rural centers and for those with a higher comorbidity burden and liver cirrhosis. However, females had 10% lower odds of mortality (AOR 0.91, 95%CI 0.83-0.99;  $P=0.03$ ).

### Predictors of discharge disposition

Significant predictors of unfavorable discharge disposition were age, race, health insurance, hospital region, and teaching status, comorbidity burden, and severity of cirrhosis (Table 2). There were 41% greater odds of unfavorable discharge for every 10-year increase in age. Unlike Blacks, who had 14%

**Table 2** Determinants of in-hospital mortality and discharge disposition of patients hospitalized with nonalcoholic fatty liver disease (NAFLD)

Characteristics		In-hospital mortality				Discharge disposition			
		aOR	LCL	UCL	P-value	aOR	LCL	UCL	P-value
Age	Per 10 year increase	1.36	1.31	1.42	<0.0001	1.41	1.39	1.43	<0.0001
Sex	Female vs. male	0.91	0.83	0.99	0.0291	1.00	0.97	1.03	0.7793
Race									
	Black vs. White	1.02	0.83	1.25	1	1.14	1.06	1.22	<0.0001
	Hispanics vs. White	0.84	0.69	1.03	0.134	0.71	0.66	0.76	<0.0001
	Asians & others vs. White	0.99	0.78	1.25	1	0.89	0.81	0.98	0.0082
Health insurance									
	Government vs. private	1.02	1.00	1.30	0.061	1.90	1.81	2.00	<0.0001
	Self-pay & others <sup>1</sup> vs. private	1.14	1.09	1.67	0.002	1.24	1.14	1.34	<0.0001
Income status									
	Lowest vs. highest quartile	1.18	0.99	1.41	0.0857	1.04	0.97	1.12	0.8205
	Second vs. highest quartile	1.10	0.92	1.30	0.9122	1.03	0.96	1.10	>0.99
	Third vs. highest quartile	1.11	0.94	1.31	0.6283	1.03	0.96	1.09	>0.99
Hospital region									
	Midwest vs. Northeast	1.18	0.96	1.45	0.2286	0.99	0.91	1.09	>0.99
	South vs. Northeast	1.22	1.01	1.48	0.0266	0.80	0.74	0.87	<0.0001
	West vs. Northeast	1.41	1.15	1.73	<0.0001	0.90	0.83	0.98	0.0102
Hospital teaching status									
	Urban non-teaching vs. rural	1.16	0.93	1.44	0.33	0.90	0.83	0.97	0.0039
	Urban teaching vs. rural	1.42	1.14	1.76	0.0003	0.83	0.77	0.90	<0.0001
Charlson-Deyo comorbidity index									
	Deyo: 1-3 vs. 0	2.34	1.93	2.84	<0.0001	1.39	1.33	1.46	<0.0001
	Deyo: >3 vs. 1-3	7.56	6.15	9.28	<0.0001	2.25	2.12	2.39	<0.0001
Liver cirrhosis									
	Compensated vs. no-cirrhosis	2.34	1.93	2.84	<0.0001	1.18	1.07	1.30	0.0001
	Decompensated vs. no-cirrhosis	7.56	6.15	9.28	<0.0001	1.19	1.09	1.31	<0.0001

<sup>1</sup>Self-pay & others: no charge, other government, Indian Health Service, Worker's compensation, other miscellaneous

aOR, adjusted odds ratio; LCL, lower confidence limit; UCL, upper confidence limit

greater odds of unfavorable discharge compared with Whites (AOR 1.14, 95%CI 1.06-1.22;  $P<0.0001$ ), Hispanics and Asians had 29% and 11% lower odds, respectively (AOR 0.71, 95%CI 0.66-0.76;  $P<0.0001$  and AOR 0.89, 95%CI 0.81-0.98;  $P=0.008$ ). Compared to the privately insured, inpatients with government insurance and those who were uninsured/self-pay had 90% and 24% higher odds, respectively, of unfavorable discharge (AOR 1.90, 95%CI 1.81-2.00;  $P<0.0001$  and AOR 1.24, 95%CI 1.14-1.34;  $P<0.0001$ ). Compared to the Northeast, the Southern and Western regions of the US had lower odds of unfavorable discharges.

### Predictors of LOS

Sex, age, Black race, health insurance, hospital region and teaching status, comorbidity burden, and liver cirrhosis were

associated with LOS (Table 3). Females had a 5% shorter LOS than males (4.35 [95%CI, 4.26-4.45] vs. 4.18 [95%CI 4.08-4.27] days;  $P<0.0001$ ) (Table 3). Unlike other races, when compared to Whites, Blacks had a 7% longer LOS (4.48 [95%CI 4.34-4.62] vs. 4.20 [95%CI 4.11-4.29] days;  $P<0.0001$ ). Government-insured and uninsured/self-pay patients had 19% and 10% longer stays, respectively (4.65 [95%CI 4.56-4.75] and 4.28 [95%CI 4.14-4.42] vs. 3.90 [95%CI 3.81-3.99] days;  $P<0.0001$ ). Individuals in the lowest and second quartile had 4% and 3% longer LOS, respectively, compared to those from the highest income quartile. Compared to inpatients in the Northeastern regions, those in the Midwest and West had 5% and 7% shorter LOS (4.20 [95%CI 4.10-4.36] and 4.11 [95%CI 3.99-4.23] vs. 4.40 [95%CI 4.27-4.54] days;  $P=0.0385$  and  $P=0.001$ , respectively). NAFLD hospitalizations in urban centers and those with higher comorbidity indices were associated with a longer LOS (Table 3).

**Table 3** Determinants of total cost and duration of hospitalization of patients admitted with nonalcoholic fatty liver disease (NAFLD)

Characteristics		Hospital charges				Length of stay			
		aMR	LCL	UCL	P-value	aMR	LCL	UCL	P-value
Age	Per 10 year increase	1.02	1.01	1.02	<0.0001	1.01	1.01	1.02	<0.0001
Sex	Female vs. male	0.93	0.92	0.94	<0.0001	0.96	0.95	0.97	<0.0001
Race									
	Black vs. White	1.00	0.94	1.07	1	1.07	1.04	1.10	<0.0001
	Hispanics vs. White	1.09	1.04	1.14	<0.0001	0.98	0.95	1.00	0.1119
	Asians & others vs. White	1.09	1.03	1.15	0.0005	1.02	0.99	1.06	0.437
Health insurance									
	Government vs. private	1.01	0.99	1.03	1	1.19	1.17	1.22	<0.0001
	Self-pay & others <sup>1</sup> vs. private	0.97	0.94	1.00	0.0379	1.10	1.06	1.13	<0.0001
Income status									
	Lowest vs. highest quartile	0.98	0.93	1.04	1	1.04	1.01	1.07	0.0028
	Second vs. highest quartile	0.99	0.94	1.05	1	1.03	1.00	1.06	0.0163
	Third vs. highest quartile	1.00	0.96	1.05	1	1.02	0.99	1.04	0.5198
Hospital region									
	Midwest vs. Northeast	0.90	0.81	0.99	0.0219	0.95	0.91	1.00	0.0385
	South vs. Northeast	1.00	0.91	1.10	1	0.99	0.95	1.03	>0.99
	West vs. Northeast	1.42	1.29	1.56	<0.0001	0.93	0.89	0.98	0.0009
Hospital teaching status									
	Urban non-teaching vs. rural	1.59	1.49	1.70	<0.0001	1.13	1.09	1.17	<0.0001
	Urban teaching vs. rural	1.83	1.70	1.96	<0.0001	1.23	1.19	1.27	<0.0001
Charleston-Deyo comorbidity index									
	Deyo: 1-3 vs. 0	1.12	1.10	1.14	<0.0001	1.14	1.12	1.16	<0.0001
	Deyo: >3 vs. 1-3	1.49	1.45	1.54	<0.0001	1.55	1.51	1.59	<0.0001
Liver cirrhosis									
	Compensated- vs. no-cirrhosis	0.97	0.90	1.03	0.5822	0.97	0.92	1.01	0.1787
	Decompensated- vs. no-cirrhosis	0.76	0.72	0.81	<0.0001	0.83	0.79	0.86	<0.0001

<sup>1</sup>Self-pay & others: no charge, other government, Indian Health Service, Worker's compensation, other miscellaneous

aMR, adjusted mean ratio; LCL, lower confidence limit; UCL, upper confidence limit

### Predictors of THC

Male sex, Hispanic and Asian races, hospital region and teaching status, and comorbidity burden were associated with a higher THC among inpatients with NAFLD (Table 3). Females had 7% lower THC than males (\$35,662 [95%CI 34,349-37,026] vs. \$38,299 [95%CI 36,872-39,7768];  $P<0.0001$ ). While Blacks (\$35,850 [95%CI 34,290-37,482]) showed no difference in THC compared to Whites (\$35,267 [95%CI 33,905-36,684];  $P>0.99$ ), Hispanics and Asians had a 9% higher THC (\$38,397 [95%CI 36,812-40,049];  $P<0.0001$  and \$38,414 [95%CI 36,485-40,445];  $P=0.0005$ ). Inpatients in the Western regions (\$49,304 [95%CI 46,970-51,755]) had 42% higher THC compared to the Northeastern regions (\$34,795 [95%CI 32,502-37,249];  $P<0.0001$ ), unlike those in the Midwest (\$31,244 [95%CI 29,647-32,927];  $P=0.022$ ) and the South (\$34,795 [95%CI 32,502-37,249];  $P>0.99$ ). Urban centers (non-teaching and

teaching) had a higher THC compared to rural centers (\$41,177 [95%CI 39,463-42,965] and \$47,298 [95%CI 45,139-49,560] vs. \$25,911 [95%CI 24,551-27,348];  $P<0.0001$ ). THC increased with the number of comorbidities (Table 3).

### Trends in hospitalizations for NAFLD


Hospitalizations with NAFLD almost tripled, with an increase of 79 NAFLD diagnoses per 100,000 hospitalizations per year, from 319/100,000 in 2007 to 902/100,000 hospitalizations in 2014 (Fig. 2A, Supplementary Table 3). All through the study period, males had both a higher frequency of NAFLD and a slightly steeper increase in the frequency of NAFLD hospitalization per year (83 vs. 76 per 100,000 hospitalizations,  $P<0.0001$ ) (see slopes in Fig. 2B). After the trend was stratified by race, Hispanics had the highest prevalence of NAFLD hospitalizations, followed

by Whites, slightly higher than Asians, while Blacks had the lowest prevalence. The rate of NAFLD hospitalizations per year followed a similar trend, with Hispanics having an average of 107 new cases of NAFLD per 100,000 hospitalizations per year compared to 48 in Blacks, and to 79.5 and 80.4 in Whites and Asians (see slopes in Fig. 2C). Privately-insured and uninsured individuals had a higher rate and trend of NAFLD hospitalizations than those with government insurance (see slopes in Fig. 2D). There was no statistically significant difference in the frequency and trends of hospitalizations for NAFLD (Fig. 2E). Finally, there was a regional trend in the frequencies of NAFLD hospitalizations (see trends and slopes in Fig. 2F), with the Western region having the highest frequencies and rate of

increase in NAFLD hospitalizations (90.26/100,000), followed by the South (81.10/100,000), then the Midwest (74.58/100,000), with the least being in the Northeastern region (67.92/100,000). The graph (Fig. 2F) reveals that the Western regions of the US have both a higher burden of NAFLD among hospitalizations and a sharper increase in this burden per year.

### Discussion

In this nationally representative study, we showed that the frequency of NAFLD among hospitalized patients tripled from



**Figure 2** Trends in hospitalizations for nonalcoholic fatty liver disease (NAFLD) in the US from 2007-2014 (A), and categorized by sex (B), race (C), health insurance (D), income quartile (E), and hospital region (F)



2007-2014, and that this increase varied significantly across demographic groups. Males, Hispanics, individuals with non-private health insurance, and those residing in the Western and Southern regions of the US were disproportionately affected, with a higher prevalence of NAFLD and poorer outcomes.

More than 60% of the patients in our study were female, suggesting that primary admissions for NAFLD were more burdensome among women; however, the HCUP-NIS had more female hospitalizations (female 59.73% vs. male 40.27%) before selecting for NAFLD. In contrast, there was a higher frequency of NAFLD hospitalizations among men than women (Fig. 2A), consistent with many studies showing that both NAFLD and nonalcoholic steatohepatitis are more prevalent among males than females [8,31-36]. We extend these studies in many ways. First, we reported that the male-predominant distribution of NAFLD observed in the community continues to the hospital setting. Second, we showed that males also had a higher rate of NAFLD hospitalization per year than women, further widening the gap in the burden of NAFLD between the sexes. The higher prevalence of NAFLD among males has been attributed to higher frequencies of insulin resistance and greater consumption of alcohol and non-diet soda among males compared to females [37]. Third, we showed that males have poorer in-hospital outcomes among NAFLD subjects: higher mortality, greater THC, and longer LOS. The cause of these poorer indexes among males may be related to health-seeking attitudes. Women utilize primary care more frequently [38-40], and may have had better management of their comorbidities, resulting in less severe presentations on admissions [41]. In addition, our data suggest that males have more comorbidities with a Charlson-Deyo score >3 (male 19.99% vs. female 17.04%). To curtail these poor trends among males, public health studies of optimal measures should be instituted, targeted towards encouraging better control of comorbidities in males in the community.

We also report that hospitalization for NAFLD was higher among Hispanics than in other racial groups (Fig. 2B), consistent with many studies [42-44]. As with the sexual disparities mentioned above, our findings extend these studies in many ways [42,43]. We demonstrated that a similar Hispanic-predominant distribution of NAFLD occurs among hospitalized patients and that Hispanics show a greater increase in the rate of NAFLD hospitalizations than other races, suggesting that an epidemic of NAFLD among the Hispanic population of the US might be imminent. The higher prevalence of NAFLD among Hispanics is an active focus for research [44]. Racial/ethnic variation in NAFLD prevalence has been partly attributed to diet, lifestyle, and genetic differences. One of the most studied genes is the *Patatin-like phospholipase domain-containing protein 3 (PNPLA3)* which encodes a membrane-bound phospholipase protein that regulates energy storage and usage. Hispanics have an allele of *PNPLA3 (rs738409[G])* that favors increased fat accumulation in the liver, unlike Blacks who have a different allele of *PNPLA3 (rs6006460[T])* that results in lower hepatic fat content [5,45]. Furthermore, Hispanics and Asians had a higher cost but better discharge disposition outcomes. The higher cost corroborates other studies by revealing the escalating cost of healthcare among Hispanics, who tend to use emergency departments more than office visits and therefore do not benefit from the preventive

medical services prioritized by primary care physicians. The better discharge dispositions among Hispanics and Asians with NAFLD compared to Whites mirror other diseases. The causes remain unclear [46,47], but may be related to the availability of support at home, financial resources or the ethnic beliefs of patients and their families. Hispanic culture treats elders with respect and views discharge to home as a more positive outcome [48]. Similarly to reports from other studies on blacks, we showed that they had a longer LOS and poorer discharge disposition, which might be related to their higher comorbidity burden [49,50]. On further analysis, our results showed that Blacks had the highest frequency of comorbidities (Deyo  $\geq 1$ : 71.8%) vs. other races: Whites (68.34%), Hispanics (60.87%), and Asians and other races (65.4%). To slow down this increasing burden of NAFLD among Hispanics, aggressive public health measures are needed, directed at Hispanic-specific risk factors such as diet, lifestyle, and health-seeking behaviors. More importantly, public health outreaches should be performed within the Hispanic community, to sensitize Hispanics to their higher susceptibility to NAFLD. Furthermore, primary care physicians could have a higher suspicion of NAFLD among their Hispanic and White patients.

Health insurance determines the type of healthcare available to the holder. Our data reports higher odds of mortality, poorer discharge disposition, and longer LOS among other groups compared to the privately-insured. Our results are similar to those of studies in 1993 and 2009, which showed that the uninsured population has higher mortality than the insured among community dwellers in the US [51,52]. Findings from another study among patients hospitalized in the US for myocardial infarction, stroke, and pneumonia are also consistent with our study [53]. These outcome disparities have been attributed to numerous factors, including difficulty in arranging discharge disposition, poor or absent outpatient management of comorbidities, lack of a primary care physician, less frequent use of subspecialists, and lower use of invasive and expensive procedures, amongst others [53,54]. We also demonstrated higher hospitalization rates and a greater number of hospitalizations/year among government-insured and uninsured/self-pay vs. privately-insured, implying that the causes of higher hospitalizations among the non-privately insured persist in the US and continue to widen the gap between privately and non-privately insured patients.

Our study observed significant variations in prevalence rate and yearly increase in NAFLD within the geographic distribution of the US. Interestingly, our observations follow the geographic trends in obesity and type 2 diabetes mellitus within the US, which are both risk factors for NAFLD [55]. Similar geographic distributions have been reported for race, income, and health insurance types [56]. Trending from Northeast to Midwest, to West and South regions of the US, there is generally higher proportion of ethnic minorities with fewer personal resources, poorer access to healthcare and fewer high-quality healthcare facilities, which might all be responsible for the higher prevalence and mortality among hospitalizations with NAFLD [56]. Furthermore, these regional disparities could reflect systematic problems at different levels of healthcare delivery, and they warrant further investigations.

Our study should be interpreted cautiously, bearing in mind the limitations of a cross-sectional study in general and those

of ICD-9 coding in particular. There may have been coding errors and imprecision in the ICD-9 implementation, resulting in underestimation of the cases. The NIS does not contain information on how NAFLD was diagnosed, including magnetic resonance imaging, liver biopsy, ultrasound, and liver function tests. Furthermore, we were unable to confirm the diagnosis by requesting the records, as the NIS is completely de-identified. The prevalence of NAFLD can differ significantly based on the diagnostic modality, and this might have affected our results. Furthermore, the difference in diagnostic modalities may contribute to variations in prevalence of NAFLD across income and region categories in our study. However, because physicians and centers in the US comply with similar practice guidelines, we do not expect significant regional variations in the diagnostic modalities of choice for NAFLD. The absence of laboratory data made it impossible to calculate the model for end-stage liver disease score and other indices of liver severity. However, we used the Charlson-Deyo and Baveno IV indexes, which are well-researched parameters, to account respectively for various non-hepatic and hepatic-specific comorbidities. Although these comorbidities were captured in ICD-9-CM, it does not capture the severity of each illness. Very few individuals from other races were in the NIS dataset, so we could not investigate the presence of disparities among those groups. Although NAFLD is a spectrum of liver disease with different outcomes, unfortunately the ICD-9-CM nomenclature does not distinguish among the subtypes, so we were unable to study how they vary with sex and race. Furthermore, the NIS does not specify the immediate cause of death, thus making it impossible for us to study the possible factors responsible for the higher death rate among males and the uninsured population. Despite these shortcomings, we believe that since the NIS encompasses numerous hospitals

across various states in the US, it provides an excellent nationally representative sample and results in reliable estimates.

In conclusion, our novel findings revealed a rising frequency of hospitalizations for NAFLD in the US. There are demographic and regional variations in the trends and clinical outcomes of hospitalizations with NAFLD from 2007-2014 in the US among males, Hispanics, Blacks, non-privately insured, and individuals in the Southern and Western regions of the US. Systemic factors at multiple levels of healthcare perpetuate these inequalities. Future studies are needed to identify and eliminate these inequalities, and aggressive public health measures are required to arrest this increasing trend in NAFLD.

## References

- Loomba R, Sanyal AJ. The global NAFLD epidemic. *Nat Rev Gastroenterol Hepatol* 2013;**10**:686-690.
- Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011;**34**:274-285.
- Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. *Hepatology* 1995;**22**:1714-1719.
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999;**30**:1356-1362.
- Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. *Hepatology* 2004;**40**:475-483.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;**116**:1413-1419.
- Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005;**129**:113-121.
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;**40**:1387-1395.
- Arab JP, Barrera F, Gallego C, et al. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients. *Ann Hepatol* 2016;**15**:721-728.
- Younossi ZM, Zheng L, Stepanova M, Henry L, Venkatesan C, Mishra A. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease. *J Clin Gastroenterol* 2015;**49**:222-227.
- Fuchs HF, Broderick RC, Harnsberger CR, et al. Benefits of bariatric surgery do not reach obese men. *J Laparoendosc Adv Surg Tech A* 2015;**25**:196-201.
- Mainous AG 3<sup>rd</sup>, Johnson SP, Saxena SK, Wright RU. Inpatient bariatric surgery among eligible black and white men and women in the United States, 1999-2010. *Am J Gastroenterol* 2013;**108**:1218-1223.
- Charlton M. Cirrhosis and liver failure in NAFLD: molehill or mountain? *Hepatology* 2008;**47**:1431-1433.
- HCUP-US NIS Overview. Available from: <https://www.hcup-us.ahrq.gov/nisoverview.jsp#data> [Accessed 2 July 2019].
- Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. *J Clin Endocrinol Metab* 2016;**101**:945-952.
- Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. *J Dermatol*

### Summary Box

#### What is already known:

- In the United States (US) community, the prevalence of nonalcoholic fatty liver disease (NAFLD) has been rising, especially among Hispanics and males
- Among hospitalized patients, little is known about the prevalence, trends and outcomes of hospitalizations with NAFLD

#### What the new findings are:

- Hospitalizations for NAFLD tripled from 2007-2014 in the US
- Hospitalization rate was higher and increased at a quicker rate/year among males, Hispanics, non-privately insured, and individuals residing in the Western region of the US
- Males had poorer outcomes compared to females
- Blacks, Hispanics and Asians had poorer outcomes compared to Whites

- Sci 2011;**63**:40-46.
17. Adejumo AC, Alliu S, Ajayi TO, et al. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: a cross-sectional study. *PLoS One* 2017;**12**:e0176416.
  18. Koebnick C, Getahun D, Reynolds K, et al. Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. *J Pediatr Gastroenterol Nutr* 2009;**48**:597-603.
  19. Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. *J Clin Gastroenterol* 2017;**51**:254-260.
  20. Adejumo AC, Adegba OM, Adejumo KL, Bukong TN. Reduced incidence and better liver disease outcomes among chronic HCV infected patients who consume cannabis. *Can J Gastroenterol Hepatol* 2018; Article ID 9430953.
  21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care* 2005;**43**:1130-1139.
  22. Greenleaf EK, Hollenbeak CS, Wong J. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: evidence from the American College of Surgeons National Cancer Database. *Surgery* 2016;**159**:1099-1112.
  23. Akanbi O, Adejumo AC, Saleem N, Francisque F, Soliman M, Ogunbayo GO. Sickle cell disease is associated with higher mortality among patients hospitalized with ischemic bowel disease. *Eur J Gastroenterol Hepatol* 2018;**30**:1027-1032.
  24. Adejumo AC, Akanbi O, Pani L. Among inpatients, ischemic bowel disease predisposes to *Clostridium difficile* infection with concomitant higher mortality and worse outcomes. *Eur J Gastroenterol Hepatol* 2019;**31**:109-115.
  25. Adejumo AC, Adejumo KL, Adegba OM, et al. Protein-energy malnutrition and outcomes of hospitalizations for heart failure in the USA. *Am J Cardiol* 2018;**123**:9290935.
  26. Akanbi O, Adejumo AC. Early endoscopy is associated with better clinical outcomes in patients hospitalized with ischemic bowel disease. *Dig Dis Sci* 2019 Mar 30 [Epub ahead of print].
  27. Thabut D, Rudler M, Dib N, et al; French Club for the Study of Portal Hypertension (CFEHTP). Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding. *Hepatology* 2015;**61**:1024-1032.
  28. May FP, Rolston VS, Tapper EB, Lakshmanan A, Saab S, Sundaram V. The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. *BMC Gastroenterol* 2016;**16**:129.
  29. HCUP Methods Series Calculating National Inpatient Sample (NIS) Variances for Data Years 2012 and Later. Available from: [https://www.hcup-us.ahrq.gov/reports/methods/2015\\_09.jsp#appa](https://www.hcup-us.ahrq.gov/reports/methods/2015_09.jsp#appa) [Accessed 2 July 2019].
  30. Hale JJ, Thompson DM, Darden PM. Calculating subset weighted analysis using PROC SURVEYFREQ and GENMOD. Available from: <http://support.sas.com/resources/papers/proceedings13/272-2013.pdf> [Accessed 2 July 2019].
  31. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. *Gastroenterology* 2003;**124**:71-79.
  32. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. *Am J Epidemiol* 2013;**178**:38-45.
  33. Schneider ALC, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. *Obesity (Silver Spring)* 2014;**22**:292-299.
  34. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003;**98**:960-967.
  35. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. *Am J Gastroenterol* 2006;**101**:76-82.
  36. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018;**67**:328-357.
  37. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. *World J Hepatol* 2014;**6**:274-283.
  38. Bertakis KD, Azari R, Helms LJ, Callahan EJ, Robbins JA. Gender differences in the utilization of health care services. *J Fam Pract* 2000;**49**:147-152.
  39. Carrière G. Consultations with doctors and nurses. *Health Rep* 2005;**16**:45-48.
  40. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract* 2016;**17**:38.
  41. Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q* 2005;**83**:457-502.
  42. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. *Medicine (Baltimore)* 2012;**91**:319-327.
  43. Ko CW, Kelley K, Meyer KE. Physician specialty and the outcomes and cost of admissions for end-stage liver disease. *Am J Gastroenterol* 2001;**96**:3411-3418.
  44. Saab S, Manne V, Nieto J, Schwimmer JB, Chalasani NP. Nonalcoholic fatty liver disease in Latinos. *Clin Gastroenterol Hepatol* 2016;**14**:5-12.
  45. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008;**40**:1461-1465.
  46. Chang PF, Ostir GV, Kuo YF, Granger CV, Ottenbacher KJ. Ethnic differences in discharge destination among older patients with traumatic brain injury. *Arch Phys Med Rehabil* 2008;**89**:231-236.
  47. Bergés I-M, Kuo Y-F, Ostir GV, Granger CV, Graham JE, Ottenbacher KJ. Gender and ethnic differences in rehabilitation outcomes following hip replacement surgery. *Am J Phys Med Rehabil* 2008;**87**:567-572.
  48. Roush CV, Cox JE. The meaning of home: how it shapes the practice of home and hospice care. *Home Healthc Nurse* 2000;**18**:388-394.
  49. Oramasionwu CU, Hunter JM, Skinner J, et al. Black race as a predictor of poor health outcomes among a national cohort of HIV/AIDS patients admitted to US hospitals: a cohort study. *BMC Infect Dis* 2009;**9**:127.
  50. Muhlestein WE, Akagi DS, Chotai S, Chambless LB. The impact of race on discharge disposition and length of hospitalization following craniotomy for brain tumor. *World Neurosurg* 2017;**104**:24-38.
  51. Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, Himmelstein DU. Health insurance and mortality in US adults. *Am J Public Health* 2009;**99**:2289-2295.
  52. Franks P, Clancy CM, Gold MR. Health insurance and mortality. Evidence from a national cohort. *JAMA* 1993;**270**:737-741.
  53. Hasan O, Orav EJ, Hicks LS. Insurance status and hospital care for myocardial infarction, stroke, and pneumonia. *J Hosp Med* 2010;**5**:452-459.
  54. DeNavas-Walt C. Income, poverty, and health insurance coverage in the United States (2005). DIANE Publishing, 2010.
  55. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA* 2003;**289**:76-79.
  56. Chandra A, Skinner JS. National Research Council, & Committee on Population. Critical perspectives on racial and ethnic differences in health in late life. National Academies Press (US), 2004. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK25524/> [Accessed 2 July 2019].

## Supplementary Tables

**Supplementary Table 1** ICD-9-CM codes used to identify clinical conditions in the study

Clinical condition	ICD-9-CM codes
NAFLD	571.8
Alcoholic liver disease	571.1, 571.2
Hemochromatosis	275.01, 275.02, 275.03
Hepatitis C virus	070.41, 070.44, 070.51, 070.54, 070.7x
Hepatitis B virus	070.2x, 070.3x
Primary biliary cirrhosis	571.6
Autoimmune hepatitis	571.42
Alcohol use	303.x, 305.0x
Toxic liver disease	571.41
Previous organ donor	V59.9
Other poorly specified liver disease	57.20, 57.21, 57.38, 789.59, 790.4, 790.5, 794.8
Previous organ recipient	V42
Charlerson-Deyo comorbidity	Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. <i>Med Care</i> 2005;43:1130-1139.
Cirrhosis	571.2, 571.5, 571.6
Ascites	789.5
Variceal bleed	456.0, 456.2
Hepatorenal syndrome	572.4
Hepatic encephalopathy	572.2
Portal hypertension	272.3
Jaundice	782.4

NAFLD, nonalcoholic fatty liver disease

**Supplementary Table 2** Ten most common primary diagnoses during hospitalizations with nonalcoholic fatty liver disease (NAFLD)

	Primary diagnosis during admissions with NAFLD	Percentage
1	Morbid obesity	8.18
2	Acute pancreatitis	5.76
3	Septicemia	2.80
4	Cholelithiasis with acute cholecystitis	2.45
5	Diverticulitis without hemorrhage	2.42
6	Pneumonia	2.06
7	Chest pain	1.61
8	Acute renal failure	1.44
9	Hepatic coma	1.41
10	Noninfectious gastroenteritis	1.24

**Supplementary Table 3** Trends in hospitalizations for nonalcoholic fatty liver disease (NAFLD): Crude (A), by Sex (B), Race (C), Health Insurance (D), Income status (E) and Region (F)

A	Year	All hospitalizations		
	2007	319.1166044		
	2008	416.4804033		
	2009	498.2456513		
	2010	581.2462595		
	2011	649.8526127		
	2012	712.9013558		
	2013	784.1985494		
	2014	902.8143487		

B	Year	Sex	
		Male	Female
	2007	343.963782	303.7857245
	2008	442.1165404	400.4353575
	2009	530.890132	477.316479
	2010	606.8087414	564.6935686
	2011	697.2999577	618.4556278
	2012	751.9840653	686.2123847
	2013	825.3875106	755.6817886
	2014	961.4787911	861.8283103

C	Year	Race		Hispanic	Asian & others
		White	Black		
	2007	345.2138078	211.5528	429.6544736	301.2815626
	2008	439.2765342	303.8477801	559.9318419	390.7543265
	2009	530.4674604	322.4453688	623.4412678	465.7056005
	2010	618.6889257	357.218618	764.9540633	537.7233048
	2011	666.2354542	403.1359322	954.987282	585.0501065
	2012	740.7396666	467.7050265	949.4851777	692.1192444
	2013	814.0259157	490.3650287	1053.124697	757.4262049
	2014	934.099089	589.5746979	1194.72306	900.1745219

D	Year	Health insurance		
		Government	Private	Uninsured
	2007	233.6445664	445.541355	410.4147548
	2008	295.5638706	590.0811364	568.6565458
	2009	375.838597	679.1373568	681.6099381
	2010	452.4974872	791.9016497	739.8659875
	2011	515.5626597	858.4872582	889.3634916
	2012	579.1305248	929.4504297	945.2226749
	2013	644.4702578	1012.832035	1026.869551
	2014	771.1176676	1156.003214	1081.955946

(Contd...)

**Supplementary Table 3 (Continued)**

E	Year	Income quartile			
		Lowest quartile	Second quartile	Third quartile	Highest quartile
	2007	287.3065702	314.7324152	349.2508911	335.2828222
	2008	367.9335575	411.602361	446.112562	449.1031602
	2009	430.7485217	487.3407596	559.4463107	545.2464027
	2010	507.685615	584.7933847	614.3664455	654.3592592
	2011	607.2054873	642.9025556	686.785994	669.7832124
	2012	674.4647119	703.8829285	753.3572514	736.4645929
	2013	746.157853	783.8542643	817.9677597	799.1685988
	2014	868.0680106	903.9591296	921.796328	931.9530444

F	Year	Hospital region			
		Northeast	Midwest	South	West
	2007	274.2737481	281.9182085	348.6454802	351.9857538
	2008	364.1914139	364.6546297	438.2644351	491.0300817
	2009	379.0960492	489.3696665	522.2464921	588.1702636
	2010	441.8142168	538.4424227	637.8965765	667.0421232
	2011	511.6211456	622.333144	673.136137	779.0749918
	2012	610.0322824	628.9297393	761.270189	821.2890235
	2013	664.8328239	708.962684	833.861041	892.8920795
	2014	765.6523808	859.1639451	931.7766417	1032.166712

Rates are per 100,000 hospitalizations